Fate Therapeutics, the San Diego-based developer of stem cell therapies, said today that CEO Paul Grayson is leaving Fate to form a new company. The new company wasn’t named in today’s release, and Fate didn’t say who will replace Grayson, although Fate’s website still lists John Mendlein as executive chairman. Grayson, who was previously a managing director with Sanderling Ventures, led Fate for three years.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
